HLA
VIR icon

Hamilton Lane Advisors’s Vir Biotechnology VIR Stock Holding History

Hamilton Lane Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,031
Closed -$336K – 95
2021
Q4 		$336K Buy
+8,031
New +$315K 0.04% 76
2021
Q3 		– Sell
-17,113
Closed -$809K – 97
2021
Q2 		$809K Buy
+17,113
New +$778K 0.25% 55

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Hamilton Lane Advisors's VIR Position: Q1 2022 in Review

Hamilton Lane Advisors sold out of Vir Biotechnology (VIR) in Q1 2022, closing a stake of 8,031 shares — an estimated $336K sold.

Hamilton Lane Advisors first reported a position in VIR in Q2 2021 and held it in 2 quarters. The position peaked at $809K in Q2 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

  • Hamilton Lane Advisors reported no remaining Vir Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Hamilton Lane Advisors sold 8,031 Vir Biotechnology shares in Q1 2022, an estimated $336K.
  • Hamilton Lane Advisors first reported a position in Vir Biotechnology in Q2 2021 and held it in 2 quarters.
  • Hamilton Lane Advisors's Vir Biotechnology position peaked at $809K in Q2 2021.
  • 204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Hamilton Lane Advisors's 13F filing for Q1 2022, filed 4 May 2022.